Patents Examined by Y. Christina Chan
  • Patent number: 5320942
    Abstract: The present invention discloses a novel cell surface marker and antigenic portions thereof; antibodies reactive with said marker; polynucleotides encoding said marker and antigenic portions thereof; methods of diagnosis and treatment using said polynucleotides and antibodies.
    Type: Grant
    Filed: October 1, 1990
    Date of Patent: June 14, 1994
    Inventors: Vito Quaranta, Shama Kajiji
  • Patent number: 5306708
    Abstract: A new antibiotic cyclic lipopeptide having the formula ##STR1## wherein R is H SEQ ID NO:1 or OH SEQ ID NO:2 and a method of producing is described. The agent has very high activity against human pathogens and is of very low mammalian toxicity.
    Type: Grant
    Filed: December 19, 1990
    Date of Patent: April 26, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Schwartz, David F. Sesin, Prakash S. Masurekar, Jerrold M. Liesch, Thomas C. Hallada, Otto D. Hensens
  • Patent number: 5298420
    Abstract: Membrane anchoring peptides are attached to the C terminal end of the heavy chain of the various immunoglobulin isotypes (IgM, IgD, IgA, IgE, or IgG). The membrane anchoring peptides span the cell membrane lipid bilayer of B cells thereby affixing the associated immunoglobulin to the cell membrane surface. The extracellular segments of these peptides are unique for different isotypes. Epitopes unique to the B cells which produce each isotype are formed, in whole or in part, by these extracellular segments. These membrane-bound immunoglobulin isotype-specific ("migis") extracellular epitopes are not present on the secreted, soluble form of the immunoglobulins, which are not bound to the cell surface by the membrane anchoring peptides. The antibodies of the invention (and other related products) specifically bind to the extracellular migis epitopes of human .mu. chain, human .delta. chain, or human .gamma. chain.
    Type: Grant
    Filed: June 19, 1992
    Date of Patent: March 29, 1994
    Assignee: Tanox Biosystems, Inc.
    Inventor: Tse W. Chang
  • Patent number: 5292668
    Abstract: A homogenous sample of identical bispecific antibody determinants, each determinant being composed of two L-H half-molecules linked by disulfide bonds, each L-H half-molecule being specific for a different antigenic determinant and including at least the F(ab') portion of a monoclonal IgG antibody. The bispecific antibody determinants are useful, e.g., in the formation of multilamellar assemblies and in enzymatic assays.
    Type: Grant
    Filed: December 5, 1990
    Date of Patent: March 8, 1994
    Assignee: Boston Biomedical Research Institute, Inc.
    Inventor: Henry P. Paulus
  • Patent number: 5286654
    Abstract: An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.
    Type: Grant
    Filed: February 3, 1993
    Date of Patent: February 15, 1994
    Assignee: Genentech, Inc.
    Inventors: Edward T. Cox, Jennie P. Mather, Mary B. Sliwkowski, Teresa K. Woodruff
  • Patent number: 5284826
    Abstract: Hydroxy-substituted [(D)Ser].sup.8 -Ciclosporin derivatives, particularly [O-(2-hydroxyethyl)(D)Ser].sup.8 -Ciclosporin, have advantageous pharmacological properties and are useful as immunosuppressants, for example in the treatment of transplant rejection and autoimmune diseases.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: February 8, 1994
    Assignee: Sandoz Ltd.
    Inventor: Marcel K. Eberle
  • Patent number: 5278143
    Abstract: Unique methods for treating interleukin-mediated edemas in living subjects are provided comprising administering an effective amount of a composition selected from the group consisting of phallotoxins, phallotoxin analogues, antamanide, or an antamanide analogue to the subject. The methods offer prophylactic and therapeutic modes of treatment for both localized and systemic interleukin-mediated edemas. The compositions of choice may be applied topically or given parenterally; and may be employed with other diverse agents for treatment of both inflammatory and non-inflammatory edemas.
    Type: Grant
    Filed: December 16, 1991
    Date of Patent: January 11, 1994
    Assignee: Trustees of Boston University
    Inventors: David Shepro, J. Steven Alexander
  • Patent number: 5275935
    Abstract: An amebic glycoconjugate is disclosed that is recognized by an Entamoeba histolytica specific monoclonal antibody The glycoconjugate is isolated from the lysates of E. histolytica trophozoites, it is phosphorylated, lipid-containing, glycosylated, migrates as a polydisperse band on SDS-PAGE between about 65-200 kDa and is specifically recognized by monoclonal antibody CC 8.6, ATCC HB 11104.
    Type: Grant
    Filed: September 10, 1992
    Date of Patent: January 4, 1994
    Assignee: Washington University
    Inventors: Samuel L. Stanley, Jr., Ellen Li
  • Patent number: 5276016
    Abstract: Short peptide of the formula:R.sup.a -Ser-Thr-Thr-Thr-Asn-Tyr-R.sup.b (I)where R.sup.a represents an amino terminal residue Ala- or D-Ala and R.sup.b represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II):R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 (II)whereR.sup.1 is an amino terminal residue Thr-, Ser-, Asn-,Leu-,Ile-,Arg- or Glu-R.sup.2 is Thr, Ser or AspR.sup.3 is Thr, Ser, Asn, Arg, Gln, Lys or TrpR.sup.4 is Tyr andR.sup.5 is a carboxy terminal amino group or a derivative thereof with a corresponding D- amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals,or a physiologically acceptable salt thereof.Such peptides bind to T4 receptors are useful in preventing viral infectivity by viruses which bind to the T4 receptors.
    Type: Grant
    Filed: August 16, 1990
    Date of Patent: January 4, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Candace B. Pert, Michael R. Ruff, William L. Farrar
  • Patent number: 5273901
    Abstract: This invention relates to novel recombinant antigenic proteins of avian coccidiosis, and fragments thereof containing antigenic determinants, and to the genes that encode the antigenic peptides. This invention also relates to vaccines made using the novel antigenic proteins of avian coccidiosis and to methods of immunizing chickens against avian coccidia.
    Type: Grant
    Filed: September 12, 1990
    Date of Patent: December 28, 1993
    Assignees: Enzon Corp., U.S. Dept. of Agriculture
    Inventors: James W. Jacobson, Robert L. Strausberg, Susan D. Wilson, Sharon H. Pope, Susan L. Strausberg, Michael D. Ruff, Patricia C. Augustine, Harry D. Danforth
  • Patent number: 5271927
    Abstract: The conjugation of antibodies to a macrocyclic conjugate compound wherein the conjugate compound has the structure (I), wherein R.sup.1 is --(CH.sub.2).sub.p --R.sup.6 --CH.sub.2).sub.q -- where p and q are the same or different and are 0, 1 or 2, and --R.sup.6 -- is --((CH.sub.2).sub.n --, where n is 0 or 1, --NH--, --O--, --S-- or (II), R.sup.1 optionally being alkyl substituted, provided that neither p nor q is 0 unless R.sup.6 is --CH.sub.2 --; R.sup.2 are --CH.sub.2 CH.sub.2 -- or --CH.sub.2 CH.sub.2 CH.sub.2 --, optionally alkyl, alkoxyalkyl or hydroxyalkyl substituted; R.sup.3 are the same or different and are --H, alkyl, hydroxyalkyl, alkoxyalkyl, carboxyalkyl, carboxyalkyl ester, phosphate, sulphonate or phosphonate; R.sup.4 is one of the compounds of formula (III) optionally alkyl substituted, wherein R.sup.7 is --H, alkyl, hydroxyalkyl, or alkoxyalkyl provided that when R.sup.4 is (III d), R.sup.3 is not carboxyalkyl, R.sup.5 is a linker, and Ab is an antibody.
    Type: Grant
    Filed: March 18, 1993
    Date of Patent: December 21, 1993
    Assignee: Celltech Limited
    Inventors: David Parker, Thomas A. Millican
  • Patent number: 5270202
    Abstract: This application discloses a novel anti-idiotypic antibody, IMelpg2 and equivalents thereof, as well as, antibody fragments, peptides or antisera capable of reacting with at least one of the idiotopes of: (a) murine monoclonal antibody MEM136 and derivatives thereof; (b) a monoclonal antibody secreted by hybridomas from any species having the same immunological specificity as antibody MEM136; or (c) any polyclonal antibodies from any species having the same immunological specificity as antibody MEM136, wherein (a), (b), or (c) is capable of reacting with a specific determinant (epitope) of a MPG antigen are described, together with their preparation and use in the diagnosis, monitoring and treatment of tumors such as melanoma or other diseased cells that express the MPG epitope recognized by antibody MEM136.
    Type: Grant
    Filed: March 12, 1991
    Date of Patent: December 14, 1993
    Inventor: Syamal Raychaudhuri
  • Patent number: 5260210
    Abstract: An in vitro model of a blood-brain barrier comprising a porous solid support upon which is disposed an essentially confluent monolayer of brain microvascular endothelial cells in contact with agents that elevate effective cyclic AMP concentrations in endothelial cells, with or without astrocyte-derived or endothelial cell-derived conditioned medium or the equivalent so that high electrical resistance tight junctions are formed between endothelial cells, and endothelial cells exhibit peripheral phalloidin staining and E-cadherin. Also disclosed is the use of agents that reduce effective cyclic AMP concentrations or interfere with the functioning of cyclic AMP or increase effective cyclic GMP concentrations to open up blood-brain barriers in vitro and in vivo, so that drugs normally excluded by such barriers may substantially penetrate such barriers. Also disclosed are uses of the model to screen for reagents with clinical utility in disorders involving brain endothelial cells.
    Type: Grant
    Filed: September 4, 1990
    Date of Patent: November 9, 1993
    Inventors: Lee L. Rubin, Seth Porter, Heidi C. Horner, Theodore A. Yednick
  • Patent number: 5260057
    Abstract: This invention describes a product obtained from the isolation and concentration of specific immunoglobulins (antibodies) derived from the mammary secretions of cows immunized with Helicobacter pylori. The product is useful in preparing formulations for the treatment and/or prevention of gastric diseases.
    Type: Grant
    Filed: December 31, 1992
    Date of Patent: November 9, 1993
    Assignee: Abbott Laboratories
    Inventors: Christopher T. Cordle, Joseph P. Schaller
  • Patent number: 5258495
    Abstract: A process for the manufacture of vancomycin.HCl which does not require preparation of a phosphate intermediate. The process consists of loading a vancomycin onto a suitable adsorbent and eluting the vancomycin solution therefrom with an ammonium solvent followed by loading the vancomycin solution onto a suitable adsorbent and eluting the purified, vancomycin solution therefrom with a solvent of alcohol and acid. The purified vancomycin is then crystallized from the solution by combining the solution with a sufficient amount of NH.sub.4 Cl to provide a pH of about 2.0 to about 3.5. The crystals are then dissolved in solution. The dissolved solution is combined with acid and the vancomycin recrystallizes from the solution.
    Type: Grant
    Filed: April 27, 1992
    Date of Patent: November 2, 1993
    Assignee: Abbott Laboratories
    Inventor: Alexander H. T. Chu
  • Patent number: 5258493
    Abstract: Disclosed herein are cyclic peptide derivatives of the formula ##STR1## wherein A is absent or the tripeptide radical Thr.rarw.Gly.rarw.Ala, R.sup.1 is benzyl or benzyl monosubstituted at position 4 of the aromatic ring with halo, hydroxy, lower alkyl or lower alkoxy, R.sup.2 and R.sup.4 each independently is hydrogen or lower alkyl, R.sup.3 is lower alkyl or lower alkyl monosubstituted with a hydroxy, R.sup.5 is lower alkyl, Y is oxo or thioxo and Z is hydroxy or NR.sup.6 R.sup.7 wherein R.sup.6 and R.sup.7 each independently is hydrogen or lower alkyl. The derivatives are useful for treating herpes infections.
    Type: Grant
    Filed: March 16, 1992
    Date of Patent: November 2, 1993
    Assignee: Bio-Mega/Boehringer Ingelheim Research Inc.
    Inventors: Julian Adams, John DiMaio, Raymond Plante
  • Patent number: 5256559
    Abstract: This invention relates to anticoagulant and platelet inhibitory compositions, combinations and methods characterized by biologically active peptides which display the anticoagulant and platelet inhibitory activities of hirudin, or analogs thereof, for therapeutic and prophylactic purposes. The methods, compositions and combinations of this invention are advantageously useful for decreasing or preventing platelet aggregation and platelet activation in a patient or a biological sample. These methods, compositions and combinations are particularly useful in patients for whom standard heparin therapy is contraindicated due to a history of heparin-induced thrombocytopenia or an antithrombin III deficiency. This invention also relates to methods, compositions and combinations for treating extracorporeal blood and for increasing platelet storage life.
    Type: Grant
    Filed: March 27, 1991
    Date of Patent: October 26, 1993
    Assignees: Biogen, Inc., Trustees of Boston University
    Inventors: John M. Maraganore, Joseph A. Jakubowski
  • Patent number: 5254671
    Abstract: Antigenic epitopes associated with the extracellular segment of the domain which anchors immunoglobulins to the B cell membrane are disclosed. For IgE, the epitopes are present on IgE-bearing B cells but not basophils or the secreted, soluble form of IgE. The epitope can be exploited for therapy and diagnosis. For example, antibodies or immunotoxins specific for the epitopes associated with the anchor domain of IgE can be used to selectively destroy or downregulate IgE-bearing lymphocytes, thus blocking IgE-mediated allergic reactions. Three different isoforms of the C-terminal segment of the human .epsilon. chain resulting from alternative mRNA splicings in the membrane exon region are disclosed, one of which is secreted and not membrane-bound.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: October 19, 1993
    Assignee: Tanox Biosystems, Inc.
    Inventor: Tse W. Chang
  • Patent number: 5248667
    Abstract: Peptides previously disclosed as useful for preventing HIV from binding to cell binding sites have now been shown to have thymoleptic qualities and to be useful for tretment of psoriasis in patients who lack antibodies against HIV.
    Type: Grant
    Filed: July 18, 1991
    Date of Patent: September 28, 1993
    Assignee: The United States of America as represented by the Secretary of the Department of Health & Human Services
    Inventors: Peter Bridge, Frederick K. Goodwin
  • Patent number: 5239057
    Abstract: The present invention is directed to a fluorescence polarization immunoassay for cyclosporin A and metabolites thereof. The present invention also relates to novel cyclosporin A derivative compounds useful in fluorescence polarization techniques. Included among the novel compounds are cyclosporin A derivatives where the amino acid in the first position is altered. The cyclosporin A derivatives are useful in forming immunogens for raising antibodies specific to cyclosporin A and metabolites thereof.
    Type: Grant
    Filed: October 15, 1991
    Date of Patent: August 24, 1993
    Assignee: Abbott Laboratories
    Inventors: Nai-Yi Wang, Philip P. Wang, Marjorie A. Morrison